

Cellular Therapy & Immunobiology Working Party

Chair: Annalisa Ruggeri Secretary: Florent Malard Vice-chair: Jürgen Kuball Statistician: Jarl Mooyaart Study Coordinator: Jorinde Hoogenboom

CTIWP

The mission of the CTIWP is to understand and exploit the biological and immunological events occurring upon HSCT at large, and to implement modern cellular therapies (CTs) based on cell and gene engineering approaches to improve patient outcomes. The CTIWP aims at fostering CT in Europe, through a continuous crosstalk between basic science findings, transplant immunobiology observations and implementation of CT approaches to answer unmet medical needs.

CTIWP at 49th Annual Meeting of EBMT

Monday, April 24th

Cell Therapy Day 09:00-17:45 Maillot

Tuesday, April 25th

Scientific Business Meeting (on-site) 07:00-08:45 Room 242 AB

Cellular Therapy and Immunobiology Working Party Session + Jon J. van Rood


Educational events in 2022

- 2nd workshop on European academic CART clinical trials
- Joint ALWP-CTIWP educational meeting
- 4th EBMT/EHA European CAR T-Cell hybrid Meeting

CELLULAR THERAPY REGISTRY

The Cellular Therapy Form was originally designed to collect data on stem cells, progenitors or mature cells, such as T-lymphocytes, unmanipulated, such as DLI, or sorted and/or cultured and/or genetically manipulated, such as CAR T-cells, used for treatment in combination with HSCT or alone, and including advanced therapeutic medicinal products (ATMP), as well as data on the clinical characteristics and outcomes of the patients. It has been revised with the primary focus on collecting data on CAR-T cells treated patient and adapted to the evolving IT now deployed to support the EBMT registry.

PLEASE CONTRIBUTE... AND REPORT YOUR PATIENTS




Number of CAR T-cell treated patients registered^{*} in the EBMT Registry

Oral presentations

- Pietro Crivello Associations between HLA Evolutionary Divergence and clinical outcome of matched related or unrelated stem cell transplantation: a study from the EBMT Cellular Therapy and Immunobiology Working Party;
- 2. Florent Malard Current use of fecal microbiota transplantation in patients with hematologic malignancies: a survey on behalf of the cellular therapy and immunobiology working-party of the EBMT;
- Vanderson Rocha Bone marrow (bm) versus peripheral-blood-stem-cell (PBSC) graft in haploidentical transplants (haplo) using post cyclophosphamide (PTCY) in adults with malignant disorders, on behalf of CTIWP EBMT;
- Esteban Arrieta Bolaños HLA-DP permissive mismatch subsets confer reduced GvHD risks and improved disease control after HCT for acute leukemia and MDS: a study by the EBMT CTIWP;

Poster presentations

- Simona Pagliuca Role of HLA evolutionary divergence in single HLAmismatched unrelated donor HCT for malignant hematological disorders: a report on behalf of the CTIWP of the EBMT
- 2. Florent Malard Outcomes after anti-BCMA CAR T-cells for multiple myeloma, a retrospective analysis on behalf of the CTIWP of the EBMT



Source: EBMT Reaistrv. Januarv 2023 *Patients identified and marked with a CAR T-cell treatment, having at least minimal data on the diagnosis and treatment.

KEY PUBLICATIONS 2022

Donor lymphocyte infusions after haploidentical stem cell transplantation with PTCY: a study on behalf of the EBMT CTIWP

N. Santoro et al., Bone Marrow Transplantation, 2023 Jan;58(1):54-60

Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation

A. Ruggeri et al., Haematologica, 2023 Feb 1;108(2):645-652

Mother Donors Improve Outcomes after HLA Haploidentical Transplantation: A Study by the Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation

L. Ruggeri et al., Transplant Cell Ther., 2022 Apr;28(4):206

3. Paolo Pedrazolli - Cell and gene therapy for Solid Tumors

CURRENT STUDIES

- Associations between HLA Evolutionary Divergence and clinical outcome of matched related or unrelated stem cell transplantation (P. Crivello)
- Role of HLA evolutionary divergence in single HLA-mismatched unrelated donor HCT for malignant hematological disorders (S. Pagliuca)
- HLA-DP permissive mismatch subsets confer reduced GvHD risks and improved disease control after HCT for acute leukemia and MDS (E. Arrieta Bolaños)
- Defining protective T-cell thresholds following allogeneic HSCT (M. Cavazzana)
- MSCs for treatment of steroid-resistant acute GvHD (L. van Hussen-Daenen)
- Evaluation of KIR-HLA class I Ligand models for donor selection (J. Schetelig)
- Bone marrow (bm) versus peripheral-blood-stem-cell (PBSC) graft in haploidentical transplants (haplo) using post cyclophosphamide (PTCY) in adults with malignant disorders, on behalf of CTIWP EBMT (V. Rocha)

The EBMT Immune Effector Cell Nursing Guidelines on CAR-T Therapy: A Framework for Patient Care and Managing Common Toxicities *R. Ellard et al., Clinical Hematology International.* 2022 Jul 8;4(3):75-88
+ see all CTIWP publications on: <u>https://www.ebmt.org/research/publications</u>

IEC Forum for nurses

The aim of the forum is to create a global support network for nurses and allied health professionals (AHPs) involved in the care of patients being treated or potentially being treated with Immune Effector Cell Therapy at all stages of the patient pathway. Learn more: <u>https://www.ebmt.org/immune-effector-cell-forum</u>

+ see all CTIWP studies on: <u>https://www.ebmt.org/research/studies</u>

UPCOMING EVENTS

24-26 November 2023: joint EBMT CTIWP – CMWP meeting 15-17 February 2024: 6th European CAR T-cell Meeting



CONTACT CTIWP

Would you like to receive information on our studies, submit a research proposal, or become a CTIWP member and help advance our research?

Feel free to contact us at: ctiwpebmt@lumc.nl

